Coherus Oncology clinical trials we track

Check company identity source

Phase 2 3 trials

Phase 1 / 2 1 trial

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Nature, frequency, and severity of adverse events (AEs) per NCI CTCAE version 5.0 or higher Description: Summaries of AEs will be based on TEAEs. A TEAE is an AE that emerges or worsens in the period from the first dose of study drug to 30 days after the last dose of study drug (Lead-In Phase). Time frame: Up to 2 years Measure: Progression Free Survival (PFS) according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) Description: PFS according to RECIST v1.1 will be evaluated in patients receiving SRF388 in combination with atezolizumab plus bevacizumab compared to placebo in combination with atezolizumab plus bevacizumab (Randomized Phase). Time frame: Up to 2 years. After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Description: A TEAE was defined as an AE that emerged or worsened in the period from the first dose of study drug to 30 days after the last dose of study drug. A summary of other non-serious AEs and all serious AEs, regardless of causality, is located in the Reported AE section. Time frame: Up to approximately 37 months.

Recruitment status changed

Before: Completed. After: Terminated.

Check registry source